Skip to main content

Actinium Pharmaceuticals, Inc.

جودة البيانات: 100%
ATNM
NYSE Manufacturing Chemicals
KWD 1.25
▼ KWD 0.01 (-0.79%)
6 months return
Momentum
Neutral
5Y revenue growth
-47.04%

النمو

Revenue Growth (5Y)
-47.04%
أقل من متوسط القطاع (1.72%)
Revenue (1Y)11.11%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-206.65%
أقل من متوسط القطاع (-54.68%)
ROIC-55.06%
Net Margin-37652.22%
Op. Margin-40274.44%

الأمان

Debt / Equity
N/A
Current Ratio7.96
Interest CoverageN/A

التقييم

PE (TTM|NTM)
-1.02 | -2.24
أعلى من متوسط القطاع (-1.49)
P/B Ratio2.52
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -47.04% annually over 5 years
Negative free cash flow of -24.68 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 58.15%
Capital intensive — 115.56% of revenue goes to capex

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

4 محللين
Buy
+360.0%
upside to target
الحالي
KWD 1.25
Consensus Target
KWD 5.75
KWD 4.00
أدنى
KWD 9.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-2.24
ربحية السهم المستقبلية
-KWD 0.56
الإيرادات المقدّرة
9.70 M

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 0.22 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 0.51 -KWD 0.22 -KWD 0.16 -KWD 0.19
Estimate -KWD 0.28 -KWD 0.35 -KWD 0.32 -KWD 0.19 -KWD 0.22 -KWD 0.24
المفاجأة -83.78% +37.59% +50.51% -1.78%

Growth

Rev 5Y: -47.04% · Earnings 1Y: N/A
Revenue Growth (1Y) 11.11% Revenue Growth (3Y) 5.41%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -47.04% Earnings Growth (5Y) N/A

Profitability

ROE: -206.65% · Net Margin: -37652.22%
Revenue (TTM) 90,000.0 Net Income (TTM) -33.89 M
ROE -206.65% ROA -56.87%
Gross Margin N/A Operating Margin -40274.44%
Net Margin -37652.22% Free Cash Flow (TTM) -24.68 M
ROIC -55.06% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 7.96
Debt / Equity N/A Current Ratio 7.96
Interest Coverage N/A Asset Turnover 0.00
Working Capital 47.53 M Tangible Book Value 13.78 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1.02 · EV/EBITDA: N/A
P/E Ratio -1.02 Forward P/E -2.24
P/B Ratio 2.52 P/S Ratio 385.22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 3.58 Fwd Earnings Yield N/A
FCF Yield -71.20%
Market Cap 34.67 M Enterprise Value -18.72 M

Per Share

EPS: -1.09 · FCF/Share: -0.79
EPS (Diluted TTM) -1.09 Revenue / Share 0.00
FCF / Share -0.79 OCF / Share -0.78
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 72.84% · CapEx/Rev: 115.56%
CapEx / Revenue 115.56% FCF Conversion 72.84%
SBC-Adj. FCF -35.20 M Growth Momentum 58.15

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 90,000.0 81,000.0 81,000.0 1.03 M 1.14 M
Net Income -33.89 M -38.24 M -48.82 M -33.02 M -24.77 M
EPS (Diluted) -1.09 -1.27 -1.83 -1.37
Gross Profit
Operating Income -36.25 M -42.12 M -51.92 M -34.10 M -24.96 M
EBITDA
R&D Expenses 21.12 M 30.05 M 38.67 M 23.14 M 18.03 M
SG&A Expenses
D&A 173,000.0 197,000.0 790,000.0 699,000.0 524,000.0
Interest Expense 3.10 M 1.09 M 190,000.0
Income Tax

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 51.78 M 76.90 M 81.45 M 114.19 M 80.39 M
Total Liabilities 43.94 M 44.14 M 45.07 M 47.71 M 6.84 M
Shareholders' Equity 7.83 M 32.76 M 36.38 M 66.48 M 73.55 M
Total Debt
Cash & Equivalents 48.00 M 72.90 M 76.68 M 108.91 M 77.83 M
Current Assets 49.38 M 74.51 M 78.26 M 110.94 M 79.75 M
Current Liabilities 7.97 M 8.15 M 8.49 M 10.63 M 6.84 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -1.0 -1.5
P/B 2.5 1.6
ROE % -206.7 -54.7
Net Margin % -37652.2 -41.5
Rev Growth 5Y % -47.0 1.7
D/E 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.12% weight